Table 3.
Regression analysis of correlation between mRSS and quantitative or categorical evaluation of organ involvement
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| N | β (95% CI) | N | β (95% CI) | |
| Lung involvement | ||||
| KL-6 | 177 | 5.14 (−3.38 to 13.7) | ||
| SP-D | 170 | 1.87* (0.27 to 3.47) | 169 | 1.87* (0.09 to 3.65) |
| %FVC | 176 | − 0.64*** (− 0.98 to − 0.30) | 175 | − 0.61** (− 0.98 to − 0.23) |
| %DLco | 171 | − 0.67*** (− 1.00 to − 0.33) | 170 | − 0.53** (− 0.89 to − 0.16) |
| Heart involvement | ||||
| BNP | 171 | 0.82 (− 0.02 to 1.66) | ||
| LVEF | 166 | 0.06 (− 0.05 to 0.17) | ||
| E/e’ | 136 | 0.02 (− 0.04 to 0.09) | ||
| RVSP | 164 | 0.11 (− 0.02 to 0.25) | ||
| Renal involvement | ||||
| eGFR | 177 | 0.44* (0.03 to 0.85) | 176 | 0.11 (− 0.25 to 0.46) |
| Gastrointestinal involvement | ||||
| Los Angeles classification | 161 | 0.02 (− 0.01 to 0.04) | ||
| Musculoskeletal involvement | ||||
| CK | 177 | 1.99 (− 0.09 to 4.07) | ||
N number of the observation, β regression coefficient, CI confidence interval. Asterisk (*) indicates statistical significance in regression analysis.*P < 0.05; **P < 0.01; ***P < 0.001